Responsive Image

 

 

Responsive Image

Oncología clínica



Integrantes del grupo

  María Teresa Abad Villar
 
 
  María Purificacion Martínez Del Prado
 
 
  María Ángeles Sala González
 
 
  Laura Sande Sardina
 
 
  Maitane Nuño Escolástico
 
 
  Patricia Novas Vidal
 
 
  Borja López De San Vicente Hernández
 
 
  María López Santillán
 
 
  Ane Zumarraga Cuesta
 
 
  Jairo Legaspi Folgueira
 
 

Publicaciones del grupo:

Garcia R,Arrieta O,Massuti B,Rodriguez D,Ortega AL,Majem M,Vicente D,Lianes P,Bosch J,Insa A,Domine M,Reguart N,Guirado M,Angeles M,Vazquez S,Bernabe R,Drozdowskyj A,Verdu A,Karachaliou N,Molina MA,Rosell R,SLCG. Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL). Lung Cancer. 2020. 150. p. 62-69. IF:5,705. (1).  

Subbiah V,Paz L,Besse B,Moreno V,Peters S,Angeles M,Antonio Lopez J,Fernandez C,Kahatt C,Alfaro V,Siguero M,Zeaiter A,Zaman K,Lopez R,Ponce S,Boni V,Arrondeau J,Delord J,Martinez M,Wannesson L,Anton A,Valdivia J,Awada A,Kristeleit R,Eugenia M,Jesus M,Sarantopoulos J,Chawla SP,Mosquera J,D'Arcangelo M,Santoro A,Villalobos VM,Sands J,Trigo J. Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment. Lung Cancer. 2020. 150. p. 90-96. IF:5,705. (1).  

Barquin M,Calvo V,Garcia F,Nunez B,Sanchez E,Serna R,Auglyt M,Carcereny E,Rodriguez D,Castro RL,Guirado M,Camps C,Bosch J,Massuti B,Ortega AL,del Barco E,Gonzalez JL,Aguiar D,Garcia R,Domine M,Agraso S,Sala MA,Oramas J,Bernabe R,Blanco R,Parejo C,Cruz A,Menasalvas E,Royuela A,Romero A,Provencio M. Sex is a strong prognostic factor in stage IV non-small-cell lung cancer patients and should be considered in survival rate estimation. Cancer Epidemiol. 2020. 67. 101737. IF:2,984. (2).  

Trigo J,Subbiah V,Besse B,Moreno V,López R,Sala MA,Peters S,Ponce S,Fernández C,Alfaro V,Gómez J,Kahatt C,Zeaiter A,Zaman K,Boni V,Arrondeau J,Martínez M,Delord JP,Awada A,Kristeleit R,Olmedo ME,Wannesson L,Valdivia J,Rubio MJ,Anton A,Sarantopoulos J,Chawla SP,Mosquera J,D'Arcangelo M,Santoro A,Villalobos VM,Sands J,Paz L. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. Lancet Oncol. 2020. 21. (5):p. 645-654. IF:41,316. (1).  

Bermejo de Las Heras B,Cortes Ramon Cajal YJ,Galve E,de la Haba J,Garcia J,Moreno F,Pelaez I,Rodriguez A,Rodriguez CA,Ruiz M,Remak E,Barra M,Rivero M,Soto J. The economic burden of metastatic breast cancer in Spain. Eur. J. Hosp. Pharm.-Sci. Pract. 2020. 27. (1):p. 19-24. IF:1,652. (4).  

Remon J,Nadal E,Domine M,Ruffinelli J,Garcia Y,Pardo JC,Lopez R,Cilleruelo A,Garcia R,Martin P,Juan O,Gonzalez JL,Provencio M,Olmedo E,Ponce S,Cumplido D,Barenys C,Majem M,Massutti B,Rodriguez D,Porta R,Sala MA,Martinez M,Lianes P,Reguart N. Malignant pleural mesothelioma: Treatment patterns and outcomes from the Spanish Lung Cancer Group. Lung Cancer. 2020. 147. p. 83-90. IF:5,705. (1).  

Manso L,Hernando C,Galan M,Oliveira M,Cabrera MA,Bratos R,Rodriguez CA,Ruiz M,Blanch S,Llombart A,Delgado JI,Alvarez I,Gallegos I,Gonzalez L,Morales S,Aguirre E,Hernando BA,Ballesteros A,Ales JE,Reboredo C,Oltra A,Gonzalez M,Santisteban M,Malon D,Echeverria I,Garcia E,Vega E,Servitja S,Andres R,Robles CE,Lopez R,Galve E,Echarri MJ,Legeren M,Moreno F. Palbociclib combined with endocrine therapy in heavily pretreated HR+/HER2- advanced breast cancer patients: Results from the compassionate use program in Spain (PALBOCOMP). Breast. 2020. 54. p. 286-292. IF:4,380. (1).

© 2021 IIS Biocruces Bizkaia